超声造影联合O‐RADS在卵巢肿瘤诊断中的研究进展

betway必威登陆网址（betway.com ）学报››2023,Vol. 44››Issue (9): 712-715.DOI:10.3969/j.issn.2097-0005.2023.09.015

超声造影联合O‐RADS在卵巢肿瘤诊断中的研究进展

李瑞娟¹(), 孟艳红²()

^1.济宁医学院临床医学院，山东济宁 272013
^2.济宁医学院附属医院超声科，山东济宁 272029

收稿日期:2022-12-19出版日期:2023-09-25发布日期:2023-10-08
通讯作者:孟艳红
作者简介:李瑞娟，硕士研究生，研究方向：妇产科超声诊断，E-mail：liruijuan2021@163.com。
基金资助:
山东省中医药科技项目(M2022248)

Research progress of contrast-enhanced ultrasound combined with O-RADS in the diagnosis of ovarian tumors

Ruijuan LI¹(), Yanhong MENG²()

^1.School of Clinical Medicine，Jining Medical University，Jining 272013，China
^2.Department of Ultrasound，Affiliated Hospital of Jining Medical College，Jining 272029，China

Received:2022-12-19Online:2023-09-25Published:2023-10-08
Contact:Yanhong MENG

摘要/Abstract

摘要：

卵巢肿瘤是常见的妇科恶性肿瘤，其组织病理学表现多样，早期诊断对提高患者生存率至关重要，对于一些恶性指征不明确的肿瘤，需要借助超声造影等多方面检查综合评价，本文总结超声造影联合卵巢附件超声报告和数据系统（ovarian-adnexal reporting and data system， O-RADS）在诊断卵巢肿瘤方面的文献，阐述其在卵巢肿瘤鉴别诊断中的最新进展，以期更好地开展临床工作。

关键词:卵巢肿瘤,超声造影,卵巢附件超声报告和数据系统

Abstract:

Ovarian tumors are common gynecological malignant tumors with diverse histopathological manifestations. Early diagnosis is crucial to improve the survival rate of patients. For some tumors with unclear malignant indications， contrast-enhanced ultrasound and other comprehensive evaluation are needed. The author summarizes the literature on contrast-enhanced ultrasound and ovarian-adnexal reporting and data system （O-RADS） in the diagnosis of ovarian tumors， and describes the latest progress in the differential diagnosis of ovarian tumors in order to carry out better clinical work.

Key words:ovarian tumors,contrast-enhanced ultrasound,O-RADS

李瑞娟, 孟艳红. 超声造影联合O‐RADS在卵巢肿瘤诊断中的研究进展[J]. betway必威登陆网址（betway.com ）学报, 2023, 44(9): 712-715.

Ruijuan LI, Yanhong MENG. Research progress of contrast-enhanced ultrasound combined with O-RADS in the diagnosis of ovarian tumors[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(9): 712-715.

参考文献30

1	Alketbi MSG， Meyer J， Robert-Yap J， et al. Levator ani and puborectalis muscle rupture： diagnosis and repair for perineal instability ［J］. Tech Coloproctol， 2021， 25（8）： 923.
2	李小利，潘志，刘传金，等. 改良恶性风险指数联合哥本哈根指数鉴别诊断卵巢肿瘤良恶性的价值［J］. 临床超声医学杂志， 2022， 24（6）： 469.
3	Huchon C， Metzger U， Bats AS， et al. Value of three-dimensional contrast-enhanced power Doppler ultrasound for characterizing adnexal masses ［J］. J Obstet Gynaecol Res， 2012， 38（5）： 832.
4	Shentu W， Zhang Y， Gu J， et al. Contrast-enhanced ultrasonography for differential diagnosis of adnexal masses ［J］. Front Oncol， 2022， 12： 968759.
5	Xun L， Zhai L， Xu H. Comparison of conventional， Doppler and contrast-enhanced ultrasonography in differential diagnosis of ovarian masses： a systematic review and meta-analysis ［J］. BMJ Open， 2021， 11（12）： e052830.
6	Hu R， Shahai G， Liu H， et al. Diagnostic value of two-dimensional transvaginal ultrasound combined with contrast-enhanced ultrasound in ovarian cancer ［J］. Front Surg， 2022， 9： 898365.
7	Liu C， Li Y， Zhu Y， et al. The value of IOTA simple rules combined with CEUS scoring system in the diagnosis of benign and malignant ovarian masses and its correlation with MVD and VEGF： a preliminary study ［J］. J Ultrasound Med， 2022， 41（12）： 2983.
8	Hu R， Zeng Q， Su X， et al. The correlation between targeted contrast-enhanced ultrasound imaging and tumor neovascularization of ovarian cancer xenografts in nude mice ［J］. J Healthc Eng， 2021， 2021： 5553649.
9	Vázquez-Manjarrez SE， Rico-Rodriguez OC， Guzman-Martinez N， et al. Imaging and diagnostic approach of the adnexal mass： what the oncologist should know ［J］. Chin Clin Oncol， 2020， 9（5）： 69.
10	Strachowski LM， Jha P， Chawla TP， et al. O-RADS for ultrasound： a user's guide， from theAJRspecial series on radiology reporting and data systems ［J］. AJR Am J Roentgenol， 2021， 216（5）： 1150.
11	Phillips CH， Guo Y， Strachowski LM， et al. The ovarian/adnexal reporting and data system for ultrasound： from standardized terminology to optimal risk assessment and management ［J］. Can Assoc Radiol J， 2023， 74（1）： 44.
12	Xu A， Nie F， Liu T， et al. Adnexal masses： diagnostic performance of contrast-enhanced ultrasound using the simple rules from the International Ovarian Tumor Analysis group［J］. Int J Gynaecol Obstet， 2022， 157（3）： 568.
13	Xu Y， Xue N， Zhang S， et al. The value of contrast-enhanced ultrasonography in differential diagnosis of benign and malignant ovarian sex cord stromal tumors ［J］. Gland Surg， 2022， 11（6）： 1086.
14	Andreotti RF， Timmerman D， Strachowski LM， et al. O-RADS US risk stratification and management system： a consensus guideline from the ACR ovarian-adnexal reporting and data system committee ［J］. Radiology， 2020， 294（1）： 168.
15	王青娟，梁茜，郑剑，等. 超声造影联合卵巢-附件超声报告和数据风险分层系统的临床应用价值［J］. 中华超声影像学杂志， 2022， 31（3）： 220.
16	Basha MAA， Metwally MI， Gamil SA， et al. Comparison of O-RADS， GI-RADS， and IOTA simple rules regarding malignancy rate， validity， and reliability for diagnosis of adnexal masses ［J］. Eur Radiol， 2021， 31（2）： 674.
17	Guo Y， Zhao B， Zhou S， et al. A comparison of the diagnostic performance of the O-RADS， RMI4， IOTA LR2， and IOTA SR systems by senior and junior doctors ［J］. Ultrasonography， 2022， 41（3）： 511.
18	祁平安. O-RADS超声分层和管理系统及超声造影在诊断附件区占位性病变中的价值［D］. 兰州：甘肃中医药大学， 2022.
19	Wang R， Li X， Li S， et al. Clinical value of O-RADS combined with serum CA125 and HE4 for the diagnosis of ovarian tumours ［J］. Acta radiol， 2023， 64（2）： 821.
20	Wu M， Wang Q， Zhang M， et al. Does combing O-RADS US and CA-125 improve diagnostic accuracy in assessing adnexal malignancy risk in women with different menopausal status？［J］. J Ultrasound Med， 2023， 42（3）：675.
21	Xie WT， Wang YQ， Xiang ZS， et al. Efficacy of IOTA simple rules， O-RADS， and CA125 to distinguish benign and malignant adnexal masses ［J］. J Ovarian Res， 2022， 15（1）： 15.
22	Amado Cabana S， Gallego Ojea JC， Félez Carballada M. Usefulness of dynamic contrast-enhanced magnetic resonance imaging in characterizing ovarian tumors classified as indeterminate at ultrasonography ［J］. Radiologia （Engl Ed）， 2022， 64（2）： 110.
23	Thomassin-Naggara I， Poncelet E， Jalaguier-Coudray A， et al. Ovarian-adnexal reporting data system magnetic resonance imaging （O-RADS MRI） score for risk stratification of sonographically indeterminate adnexal masses ［J］. JAMA Netw Open， 2020， 3（1）： e1919896.
24	Melamud K， Hindman N， Sadowski E. Ovarian-adnexal reporting and data systems MR imaging：nuts and bolts［J］. Magn Reson Imaging Clin N Am， 2023， 31（1）： 79.
25	Nougaret S， Lakhman Y， Bahadir S， et al. Ovarian-adnexal reporting and data system for magnetic resonance imaging （O-RADS MRI）： genesis and future directions［J/OL］. Can Assoc Radiol J. （2022-10-16）［访问日期缺失］. . DOI：10.1177/08465371221121738.
26	Mohamadian A， Moradi B. Simplified approach for ovarian-adnexal reporting and data system MRI risk stratification system ［J］. Korean J Radiol， 2022， 23（11）： 1115.
27	Sebastià C， Cabedo L， Fusté P， et al. The O-RADS MRI score for the characterization of indeterminate ovarian masses： from theory to practice ［J］. Radiologia （Engl Ed）， 2022， 64（6）： 542.
28	Pi Y， Wilson MP， Katlariwala P， et al. Diagnostic accuracy and inter-observer reliability of the O-RADS scoring system among staff radiologists in a North American academic clinical setting ［J］. Abdom Radiol （NY）， 2021， 46（10）： 4967.
29	Cao L， Wei M， Liu Y， et al. Validation of American college of radiology ovarian-adnexal reporting and data system ultrasound （O-RADS US）： analysis on 1054 adnexal masses ［J］. Gynecol Oncol， 2021， 162（1）： 107.
30	Luo H， Lin Z， Wu L， et al. Application of O-RADS ultrasound lexicon-based logistic regression analysis model in the diagnosis of solid component-containing ovarian malignancies ［J］. Biomed Res Int， 2022， 2022： 7187334.